Vilaprisan (BAY1002670; BAY10-02670) is a synthetic steroidal agent acting as a selective progesterone receptor modulator which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids. It is a potent and selective orally bioavailable progesterone receptor modulator that holds the promises of long-term treatment of patients with symptomatic uterine fibroids. BAY1002670 in subnanomolar concentrations exhibits a highly selective binding profile and antagonistic activity for the PR. These properties are also reflected in its action in two progesterone-dependent animal models that assess the termination of pregnancy and endometrial transformation. In a human fibroid xenograft model BAY 1002670 showed a marked dose-dependent reduction of fibroid tumour weight gain of 95% at a dose of 3 mg/kg/day.

纯度：≥98%

CAS：1262108-14-4